It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with disease progression compared with best supportive care alone (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) changes proportion of people with disease progression compared with hydroxycamptothecin (very low certainty).
It is very uncertain whether recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu)… changes proportion of people with disease progression compared with transarterial chemoembolisation (very low certainty).
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes proportion of people with disease progression compared with percutaneous ethanol injection (very low certainty).
The review found no eligible studies for this question.